US 12,263,233 B2
Compositions and methods for modulating Myc target protein 1
Kyunghee Choi, St. Louis, MO (US); Ashraf Ul Kabir, St. Louis, MO (US); and Karen Krchma, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Oct. 19, 2021, as Appl. No. 17/451,428.
Claims priority of provisional application 63/093,595, filed on Oct. 19, 2020.
Prior Publication US 2022/0143220 A1, May 12, 2022
Int. Cl. C12N 15/113 (2010.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 48/0066 (2013.01) [A61P 35/00 (2018.01); C12N 15/113 (2013.01)] 31 Claims
OG exemplary drawing
 
1. A method of treating a solid-tumor cancer in a subject in need thereof, the method comprising:
administering to the subject a composition comprising an shRNA or siRNA specific for Myc target protein 1 (MYCT1) mRNA, wherein the shRNA or siRNA reduces MYCT1 protein expression in endothelial cells at a tumor of the solid-tumor cancer, which reduces tumor angiogenesis and increases cytotoxic T cell transendothelial migration at the tumor in the subject.